Coagulation and Fibrinolysis Assessed in Splenic Injury Patients
|
By LabMedica International staff writers Posted on 19 May 2021 |

Image: The Star Evolution coagulation analyzer (Photo courtesy of Diagnostica Stago)
The most frequently injured solid organ following blunt abdominal trauma is the spleen. Splenectomy was a standard surgical procedure for splenic injury until the mid‐20th century. However, thrombotic and infectious complications following splenectomy were demonstrated by many studies.
Thrombocytosis, alterations of coagulation and fibrinolysis contribute to hypercoagulability and thromboembolism. Platelet (PLT) count, fibrinogen (FIB), D‐dimers (D‐D), fibrinogen/fibrin degradation products (FDP), antithrombin III (AT III) are key markers of coagulation and fibrinolytic activity. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) are used for routine coagulation testing.
Emergency Medicine Specialist at the University of Science and Technology of China (Hefei, China) included in a study 38 blunt splenic injury (BSI). Splenic artery embolization (SAE) was performed if the splenic injury was classed as grade III or greater and had no requirement of immediate surgery.
Blood samples were collected in tubes containing EDTA for PLT count and Hb, hematocrit (Hct) determinations, which were determined using Sysmex XE‐5000 automated hematology analyzer (Sysmex, Kobe, Japan). Samples were collected in tubes containing 3.2% sodium citrate and then centrifuged at 2,000 rpm for 20 minutes to obtain plasma, which was used for determining coagulation and fibrinolysis parameters. FIB, D‐D, FDP, AT III, PT, APTT, and TT were measured on the STA‐R Evolution automated coagulation analyzer with identical commercial kit (Diagnostica Stago, Asnieres, France).
The medical team reported that the technical success rate of SAE and the splenic salvage rate were 100%. There was no mortality. Compared with pre‐SAE values, the levels of PLT, FIB, D‐D, and FDP increased significantly at three days and seven days after SAE. However, AT III, PT, APTT, TT, Hb, and Hct showed no statistically significant difference at one day, three days, and seven days after SAE.
The authors concluded that they had demonstrated that PLT significantly increased and activation of coagulation and fibrinolysis took place in BSI patients undergoing SAE. These alterations might have contributed to the increased risk of thrombotic complications, especially three days and seven days after SAE. Despite SAE as a critical treatment is used extensively in BSI patients and has increased the success rate of NOM, thromboembolism following SAE should be considered and thrombotic prophylaxis should be recommended. The study was published on May 6, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Science and Technology of China
Sysmex
Diagnostica Stago
Thrombocytosis, alterations of coagulation and fibrinolysis contribute to hypercoagulability and thromboembolism. Platelet (PLT) count, fibrinogen (FIB), D‐dimers (D‐D), fibrinogen/fibrin degradation products (FDP), antithrombin III (AT III) are key markers of coagulation and fibrinolytic activity. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) are used for routine coagulation testing.
Emergency Medicine Specialist at the University of Science and Technology of China (Hefei, China) included in a study 38 blunt splenic injury (BSI). Splenic artery embolization (SAE) was performed if the splenic injury was classed as grade III or greater and had no requirement of immediate surgery.
Blood samples were collected in tubes containing EDTA for PLT count and Hb, hematocrit (Hct) determinations, which were determined using Sysmex XE‐5000 automated hematology analyzer (Sysmex, Kobe, Japan). Samples were collected in tubes containing 3.2% sodium citrate and then centrifuged at 2,000 rpm for 20 minutes to obtain plasma, which was used for determining coagulation and fibrinolysis parameters. FIB, D‐D, FDP, AT III, PT, APTT, and TT were measured on the STA‐R Evolution automated coagulation analyzer with identical commercial kit (Diagnostica Stago, Asnieres, France).
The medical team reported that the technical success rate of SAE and the splenic salvage rate were 100%. There was no mortality. Compared with pre‐SAE values, the levels of PLT, FIB, D‐D, and FDP increased significantly at three days and seven days after SAE. However, AT III, PT, APTT, TT, Hb, and Hct showed no statistically significant difference at one day, three days, and seven days after SAE.
The authors concluded that they had demonstrated that PLT significantly increased and activation of coagulation and fibrinolysis took place in BSI patients undergoing SAE. These alterations might have contributed to the increased risk of thrombotic complications, especially three days and seven days after SAE. Despite SAE as a critical treatment is used extensively in BSI patients and has increased the success rate of NOM, thromboembolism following SAE should be considered and thrombotic prophylaxis should be recommended. The study was published on May 6, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Science and Technology of China
Sysmex
Diagnostica Stago
Latest Hematology News
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreMolecular Diagnostics
view channel
Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer
Bladder cancer is among the most common malignancies in the United States, with about 85,000 new cases each year. The muscle-invasive form accounts for roughly one quarter of diagnoses and carries a high... Read more
Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
Datar Cancer Genetics (DCG; Nashik, India), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has received U.... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more








